Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer
Abstract
4%–9% of prostate cancers harbor homozygous deletions of the androgen-induced tumor suppressor gene, promyelocytic leukemia zinc finger (PLZF, ZBTB16). PLZF loss induces an in vitro phenotype of castration resistance and enzalutamide resistance. The association of low expression of PLZF and clinical outcomes is unclear.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2019
- Source ID
- 10.1158/1055-9965.epi-18-1014
Entities
People
- Goutam Chakraborty
- Gwo-shu Mary Lee
- Konrad H Stopsack
- Lorelei A. Mucci
- Philip W. Kantoff
- Svitlana Tyekucheva
- Travis Gerke
- Wassim Abida
- Ying Z. Mazzu
Organizations
- Brigham and Women's Hospital
- Dana Farber Harvard Cancer Center
- Dana–Farber Cancer Institute
- H. Lee Moffitt Cancer Center & Research Institute
- Harvard University
- Memorial Sloan Kettering Cancer Center
- National Institutes of Health
- United States Department of Defense